Navigation Links
Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Date:7/21/2008

KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) has rescheduled the time of its conference call and webcast to review the sales and earnings results for the 2008 second quarter to approximately 4:45 p.m. (EDT) from 8 a.m. today. The quarterly financial results will be issued today, July 21, 2008, after the close of the New York Stock Exchange.

Schering-Plough made the second-quarter earnings schedule change because Terje Pedersen, M.D., Ph.D., Chief, Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway, and the primary investigator of Simvastatin plus Ezetimibe in Aortic Stenosis study (SEAS), has announced that he will present an update on the study at 1 p.m. (U.S. EDT) today.

To listen live to the Schering-Plough second quarter earnings conference call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID #50992673. A replay of the call will be available beginning later on July 21 through 5 p.m. on July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #50992673. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on Aug. 20.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
2. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
3. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
4. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
5. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
6. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
7. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
8. Schering-Plough CEO Buys $2 Million in Common Shares
9. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
10. Schering-Plough Reports Financial Results for First Quarter of 2008
11. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Global Strategic Business Report" report to their offering. ... This report analyzes the ... Million. Annual estimates and forecasts are provided for the period 2014 ... secondary research. The report profiles 25 companies including ...
(Date:3/24/2017)... , March 24, 2017 Agenus Inc. ... immune checkpoint antibodies and cancer vaccines, today announced participation ... 7 th  Annual William Blair and Maidstone Life Sciences ... Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert B. ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... CT (PRWEB) , ... March 23, 2017 , ... ... LLC, was recently selected by the Connecticut Technology Council (CTC) as a 2017 ... at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes ...
Breaking Biology Technology:
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):